Veracyte Announces Second Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Veracyte (VCYT) Tops Q2 EPS by 9c, Revenues Beat; Boosts FY18 Revenue Guidance
July 23, 2018 4:11 PM EDTVeracyte (NASDAQ: VCYT) reported Q2 EPS of ($0.18), $0.09 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $20.56 million.
We delivered another exceptional quarter of revenue and genomic test volume growth, said Bonnie Anderson, chairman and chief executive officer of Veracyte. We saw strong growth in our Afirma business where our deep... More
